1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Kronos Bio, Inc.
  6. Summary
    KRON   US50107A1043

KRONOS BIO, INC.

(KRON)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
3.810 USD   +7.32%
07:07aINSIDER BUY : Kronos Bio
MT
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
3.63(c) 3.94(c) 3.76(c) 3.55(c) 3.81(c) Last
233 937 464 964 585 547 3 338 069 1 694 238 Volume
-7.16% +8.54% -4.57% -5.59% +7.32% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash position 2022 73,0 M - -
P/E ratio 2022 -1,24x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -186 M - -
Net Debt 2023 9,26 M - -
P/E ratio 2023 -1,10x
Yield 2023 -
Capitalization 201 M 201 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 96
Free-Float 85,5%
More Financials
Company
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered,... 
More about the company
Ratings of Kronos Bio, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about KRONOS BIO, INC.
07:07aINSIDER BUY : Kronos Bio
MT
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
GL
05/12Kronos Bio to Feature Entospletinib, Lanraplenib Investigational Inhibitors at European..
MT
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
GL
05/04KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
GL
05/04Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/21KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08Kronos Bio Says Preclinical Data Shows Potential for Its Treatment of Certain Cancer Ty..
MT
04/08Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Addition..
GL
04/08Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Addition..
GL
04/08Kronos Bio, Inc. Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Ad..
CI
03/08Kronos Bio's Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical ..
GL
More news
News in other languages on KRONOS BIO, INC.
07:07aACHAT D'INITIÉS : Kronos Bio
05/12Kronos Bio présentera les inhibiteurs expérimentaux Entospletinib et Lanraplenib au Con..
05/04Kronos Bio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/08Kronos Bio déclare que les données précliniques montrent le potentiel de son traitement..
04/08Kronos Bio, Inc. présente à l'AACR des données précliniques sur l'inhibiteur oral de CD..
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,55 $
Average target price 29,50 $
Spread / Average Target 731%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-73.88%201
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418